Fig. 3From: Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trialsIn 19del mutation subgroup, forest plots of PFS (A) and OS (B) between combination therapy and monotherapy. In L858R mutation subgroup, plots of PFS (C) and OS (D) between combination therapy and monotherapyBack to article page